Zinc supplementation improves ALT level in chronic hepatitis C patients during combination therapy of PEG-interferon .ALPHA.-2b and ribavirin
-
- Murakami Y
- Department of Nutritional Science, Faculty of Health and Welfare Science Okayama Prefectural University
-
- Koyabu T
- Department of Nutritional Science, Faculty of Health and Welfare Science Okayama Prefectural University
-
- Kawashima A
- 奈良女子大学大学院人間文化研究科
-
- Kakibuchi N
- 瀬戸内短期大学食物栄養学科
-
- Kawakami T
- Department of Nutritional Science, Faculty of Health and Welfare Science Okayama Prefectural University
-
- Takaguchi K
- 香川県立中央病院内科
-
- Kita K
- 喜田医院
-
- Okita M
- Department of Nutritional Science, Faculty of Health and Welfare Science Okayama Prefectural University
Bibliographic Information
- Other Title
-
- C型慢性肝炎のPEG‐IFN α‐2b/ribavirin併用療法における亜鉛投与のALT値改善効果(投与開始8週目までの検討)
Search this article
Abstract
We investigated the effects of zinc supplementation on the clinical observations in chronic hepatitis C patients during PEG-interferon α-2b plus ribavirin (PEG-IFN/R) therapy. Patients were randomly allocated to receive daily 150 mg polaprezinc (Zn group, n=11) or no supplement (control, n=12) in addition to PEG-IFN/R therapy and daily antioxidant vitamin supplementation (300 mg of vitamin E and 600 mg of vitamin C). Ten of 11 patients (91%) in Zn group and 7 of 12 (58%) control patients showed decrease in ALT levels (</=35 U/l) after 8 weeks of therapy. This observation indicates that polaprezinc supplementation may induce antioxidative functions in liver which resulted in improvement of hepatocyte injury during PEG-IFN/R therapy.
Journal
-
- Kanzo
-
Kanzo 47 (3), 165-, 2006
The Japan Society of Hepatology
- Tweet
Keywords
Details
-
- CRID
- 1390001204790341504
-
- NII Article ID
- 10017560591
-
- NII Book ID
- AN00047770
-
- COI
- 1:CAS:528:DC%2BD28XltVGit70%3D
-
- ISSN
- 18813593
- 04514203
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed